SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series A, Series B and Series C warrants to purchase shares of its common stock in an underwritten public offering. Sorrento also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrant combinations, which consist of Series A, Series B and Series C warrants, offered in the public offering on the same terms and conditions. All of the shares of common stock and Series A, Series B and Series C warrants to purchase shares of common stock to be sold in the offering are to be sold by Sorrento. Sorrento curr
